Healthcare Business Recap: Humana’s VFW Deal, Inovio’s Clinical Results

Humana (NYSE:HUM) has reached an exclusive agreement with the Veterans of Foreign Wars, to become the exclusive national Medicare Advantage plan carrier for the organization. Humana will now be able to market Medicare Advantage health plans to the VFW’s more than 700,000 members and their spouses who are eligible for Medicare, and also to provide guidance for those who will soon be qualified.

Health Care REIT’s (NYSE:HCN) portfolio modifications should allow its earnings and cash flow growth to speed up more quickly than those of its peers, says RBC Capital. The firm thus anticipates that the stock’s multiple will rise over time and it keeps an Outperform rating.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Inovio Pharmaceuticals (AMEX:INO) jump on the announcement that Phase I clinical results indicated that its DNA-based synthetic vaccine VGX-3100 is not only capable of boosting immune responses to antigens from high risk types of human papillomavirus infection, but also to kill cells that were changed by the virus into precancerous dysplasias.

Myriad Genetics (NASDAQ:MYGN) reports that a study which was published in the British Journal of Cancer has shown, with highly statistically significant results, the ability of its Homologous Recombination Deficiency Assay to detect the loss of DNA repair in ovarian tumors.

Don’t Miss: Is Merck’s Stock a Buy Now?